Ipsen (XPAR:IPN) Construction In Progress : €0 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Ipsen Construction In Progress?

Ipsen's quarterly construction in progress declined from Dec. 2022 (€147 Mil) to Jun. 2023 (€139 Mil) and declined from Jun. 2023 (€139 Mil) to Dec. 2023 (€0 Mil).

Ipsen's annual construction in progress increased from Dec. 2021 (€107 Mil) to Dec. 2022 (€147 Mil) but then declined from Dec. 2022 (€147 Mil) to Dec. 2023 (€0 Mil).

Ipsen Construction In Progress Historical Data

The historical data trend for Ipsen's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Construction In Progress Chart

Ipsen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

129.80

90.60

106.70

146.70

Ipsen Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Construction In Progress	Get a 7-Day Free Trial															106.70	123.90	146.70	138.80	-

Ipsen Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Ipsen (XPAR:IPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (XPAR:IPN) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA 0MH6:UK I7G:Germany

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.